Clinical trialPhase 1Terminated
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
- Outcome
- Stopped earlySponsor decision (Business decision)
- Phase
- Phase 1
- Status
- Terminated
- Study type
- Interventional
- Start
- 2 March 2022
- Expected end
- 29 April 2026
- Enrollment
- 13 participants
- Sites
- 1
- Primary outcomes
- Type, frequency, severity, and attribution of AEs/SAEs as assessed by CTCAE v 5.0; Occurrence of dose-limiting toxicities.; Recommended expansion dose of VCN-01 administered in combination with huCART-meso cells; Occurrence of treatment-limiting toxicities (TLTs); Comparison of the safety profiles of the two treatment arms via descriptive analysis
- Sponsor
- Other
- Results posted
- No
- Last update
- 29 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a single-center phase 1 study to evaluate the safety and feasibility of huCART-meso cells given in combination with VCN-01 in patients with unresectable or metastatic pancreatic adenocarcinoma and serous epithelial ovarian cancer.
Detailed description public domain (ClinicalTrials.gov)
This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCARTmeso cells when given in combination with VCN-01. Dose Finding Phase: This study was initiated using a 3+3 dose (de)escalation design in order to explore the initial safety of these drugs when given in combination, as well as to establish the recommended expansion dose of VCN-01 in this setting. Expansion Phase: The trial was expanded to include two parallel treatment arms further exploring the dosing sequence and schedule of these two investigational products when given in combination.